Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
FT-002 is an intraocular injection of recombinant AAV virus carrying the gene that expresses active functional proteins and repairs damaged retinal cell structure and function. It treat patients with X-linked retinitis pigmentosa caused by RPGR gene mutation.
Lead Product(s): FT-002
Therapeutic Area: Genetic Disease Product Name: FT-002
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2023
Details:
FT-003 is a gene therapy product for the treatment of neovascular age-related macular degeneration. It has the potential to provide durable expression of therapeutic levels of intraocular protein and maintaining the vision of patients.
Lead Product(s): FT-003
Therapeutic Area: Ophthalmology Product Name: FT-003
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
Details:
FT-001 is administered by injection into the subretinal space of the eye that delivers a functional copy of the human RPE65 gene. FT-001, for the treatment of Leber Congenital Amaurosis-2, a severe inherited retinal disease related to RPE65 gene mutation.
Lead Product(s): FT-001
Therapeutic Area: Rare Diseases and Disorders Product Name: FT-001
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
Details:
Frontera’s FT-001 is an AAV gene therapy product administered by a one-time injection into the subretinal space of the eye that delivers a functional copy of the human RPE65 gene to the nuclei of the patient’s retinal cells.
Lead Product(s): FT-001
Therapeutic Area: Ophthalmology Product Name: FT-001
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022